-
Capital, M&A & Industry Strategy2 days agoNLS Days 2026: what’s dealmaking like in the Nordics?
At NLS Days 2026, life science companies and a record number of investors attended to showcase data, partner, and raise funding. The post NLS Days 2026:...
-
Capital, M&A & Industry Strategy2 days agoEncoded raises $275m for Dravet therapy and other financings
Our round-up of biotech financings is headed by Encoded, which has raised $275m to advance its gene therapy for Dravet syndrome into pivotal trials.
-
Capital, M&A & Industry Strategy3 days agoNovartis’ board faces investor scrutiny after M&A misfires and R&D flops
Back-to-back failures of multiple late-phase trials have raised questions about how Novartis has deployed capital in pursuit of drugs to drive growth through the 2030s.
-
Capital, M&A & Industry Strategy3 days agoNovartis DM1 miss raises stakes for next wave of DMPK readouts
BIOCENTURY | PRODUCT DEVELOPMENTNOVARTIS DM1 MISS RAISES STAKES FOR NEXT WAVE OF DMPK READOUTSFour upcoming readouts will test the translational potential of additional DM1 candidates as...
-
Capital, M&A & Industry Strategy3 days agoBiotech’s 2026 IPOs deliver broad gains through August
BIOCENTURY | DATA BYTEBIOTECH’S 2026 IPOS DELIVER BROAD GAINS THROUGH AUGUST18 of 21 are trading above their IPO price
-
Capital, M&A & Industry Strategy3 days agoRevvity Signs Agreement to Acquire Human Cell Design
As wet-lab validation becomes increasingly important to support artificial intelligence-enhanced science, research science points out that human-relevant cell models provide an important foundation for testing and...
-
Capital, M&A & Industry Strategy3 days agoSTAT+: Pharmalittle: We’re reading about a Novartis investor seeking a shake-up, a Gilead setback, and more
A major Novartis shareholder has called for a shake-up of the drugmaker's board after its shares suffered a record fall following trial setbacks
Carbon Dots Emerge as a Powerful Weapon Against Superbugs and Biofilms
Your Zip Code May Shape Your Breast Cancer Tumor’s Genetics and Your Survival Odds
Azithromycin Resistance in Gonorrhea Shifts Genetic Ground, Challenging Molecular Surveillance
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
